ライフサイエンスコーパス: IND

1 IND administration induced significant ulceration, bleed

2 IND evoked robust phosphorylation of Kv1.3, as well as i

3 IND fruit diaspores (containing nonmucilaginous seeds) d

4 IND-GLY significantly increased mean correlation as meas

5 IND-treated mice had an increased short- and long-term o

6 IND-VFQ scores, on average, increased by 9.2 points from

7 New Drug status from the FDA in April 1992 (IND no. 34671; sponsor, Ann R Kennedy), and studies to e

8 , the same hypothetical impact on world 2050 IND could be achieved by decreasing CH4 emissions by 46%

9 after final US Food and Drug Administration IND approval, reducing the overall timeline by about 3 m

10 and ABA-related gene expression and altered IND pericarp biomechanical properties.

11 Although IND did not bind these sites simultaneously, the presenc

12 Although IND/A alone caused villous atrophy, more-widespread smal

13 Although an IND is not required for use of FMT to treat RCDI, an IND

14 However, the radiation exposures from an IND may be complex due to mixed fields of neutrons and p

15 AR-12 is an IND-approved derivative of celecoxib that demonstrated p

16 tory requirements and successfully obtain an IND before they can begin to use FMT as part of their cl

17 ng, preclinical, and clinical sections of an IND for allogeneic islets of Langerhans to treat type 1

18 hat supported the filing and clearance of an IND for the treatment of cancer.

19 Food and Drug Administration approval of an IND.

20 ot required for use of FMT to treat RCDI, an IND is strongly encouraged and may ultimately be require

21 sing a GMP-produced wild-type virus under an IND.

22 Similarly, 4MP and IND yielded type II binding spectra that reflected the a

23 st, all calves coinfected with WD534tc/C and IND/A (n = 2) developed diarrhea and shed both viruses,

24 rred in calves coinfected with WD534tc/C and IND/A.

25 istration of eicosapentaenoic acid (EPA) and IND.

26 and 2.51-fold (95% CI 1.32-4.79) for IND and IND/TIO, respectively.

27 In addition, SPT and IND promote the expression of specific core cell-cycle r

28 The NEI-VFQ and IND-VFQ scores for Indian participants were correlated h

29 Vision-related QoL (NEI-VFQ and IND-VFQ) and health-related QoL (HRQoL; physical compone

30 der an Investigational New Drug application (IND).

31 ea share identical function with Arabidopsis IND since ethyl methanesulphonate (EMS) mutant alleles a

32 EPA significantly attenuated IND-induced oxidative damage and apoptosis.

33 s in ventilation, perfusion, and VQM between IND-GLY and placebo were compared using analysis of vari

34 to demonstrate that the BraA.IND.a and BolC.IND.a genes from B. rapa and B. oleracea share identical

35 opment approach to demonstrate that the BraA.IND.a and BolC.IND.a genes from B. rapa and B. oleracea

36 nt suggesting a general role of Brassicaceae IND genes in preventing valve margin cells from adopting

37 gnificantly correlated with Rasch-calibrated IND-VFQ scores (r=-0.54) and with visual field MD, prese

38 However, in the absence of a tumor context, IND enhanced the intrinsic suppressive function of MDSCs

39 tients were randomized to receive once-daily IND/GLY (110/50 mug) for 14 days, followed by 14 days of

40 FUL technique to assess the effect of 14-day IND-GLY treatment versus placebo on regional measurement

41 a metric we term international natural debt (IND).

42 s were classified into initial nasal defect (IND), initial parafoveal scotoma (IPFS), and combined na

43 optimized a 7 d intranasal insulin delivery (IND) in awake mice to ascertain the biochemical and beha

44 terrorism using improvised nuclear devices (IND) necessitate the development of biodosimetry assays

45 ackages supporting Investigational New Drug (IND) and Biologics License (BLA) applications and the de

46 ministration (FDA) investigational new drug (IND) application, unless specifically exempt from IND re

47 ficant increase in investigational new drug (IND) applications for the use of allogeneic islets of La

48 creasing number of Investigational New Drug (IND) applications for therapeutic monoclonal antibodies

49 d clinically under investigational new drug (IND) applications submitted to the U.S. Food and Drug Ad

50 on hERG channels for investigative new drug (IND) applications.

51 can elapse between investigational new drug (IND) approval by the US Food and Drug Administration and

52 ossess an approved investigational new drug (IND) permit to administer FMT for the purpose of conduct

53 ology to patients, investigational new drug (IND)-enabling studies in NHPs were initiated.

54 Currently, investigational new drug (IND)-enabling studies with 1 are underway.

55 ry personnel as an investigational new drug (IND).

56 ), achalasia, intestinal neuronal dysplasia (IND), chronic intestinal pseudo-obstruction (CIPO), and

57 the request of ALVR109 through an emergency IND.

58 ues, we have initiated a Phase I Exploratory IND study to determine the biodistribution of the fibril

59 ams initiated between 2000 and 2009, we find IND-to-approval rates reduced to 23% with median develop

60 6-7.29) and 2.51-fold (95% CI 1.32-4.79) for IND and IND/TIO, respectively.

61 application, unless specifically exempt from IND requirements, or under the direct oversight of a Rad

62 tained by pericarp (fruit coat) removal from IND fruits.

63 al, in a median time of about six years from IND receipt to approval.

64 oval, in a median time of about 6 years from IND receipt to approval.

65 d morphs), the dispersed indehiscent fruits (IND fruit morphs), and the bare non-mucilaginous M- seed

66 orph (dehiscent [DEH] vs indehiscent fruits [IND]).

67 Further IND-generating preclinical experiments will advance rAAV

68 Furthermore, IND suppressed IFN-gamma production and PGE2 increased I

69 chodilation with indacaterol/glycopyrronium (IND/GLY) significantly reduced hyperinflation, which tra

70 n FEV1 /cumulative dose), when comparing ICS/IND/TIO to ICS/IND.

71 ic compared to single dosing with either ICS/IND (P<.005) or ICS/IND/TIO (P<.05).

72 e dosing with either ICS/IND (P<.005) or ICS/IND/TIO (P<.05).

73 ive dose), when comparing ICS/IND/TIO to ICS/IND.

74 n modeling showed a 3.2-point improvement in IND-VFQ score for every 5-letter improvement in visual a

75 use IND to assess the relative reduction in IND from choosing between CO2(f) and CH4 control measure

76 GS-5718 was safe and well-tolerated in IND-enabling preclinical animal toxicity studies, demons

77 iotropium (IND/TIO) vs ICS with Indacaterol (IND) over 4 weeks with challenge performed after first a

78 Bicyclic indazole (IND) inhibited catalysis through a single CYP2E1 site (K

79 ridine (SAP), benzothiazole (BZT), indazole (IND), and tetrahydroindazole (THI) series as novel ITK i

80 ial symmetry, SPATULA (SPT) and INDEHISCENT (IND).

81 he valve margin identity factor INDEHISCENT (IND) is responsible for forming the auxin minimum by coo

82 the fruit-tissue identity gene, INDEHISCENT (IND), is responsible for expansion of its expression dom

83 Here, we identify INDEHISCENT (IND), an atypical bHLH protein, that is necessary for fr

84 Arabidopsis is dependent on the INDEHISCENT (IND) gene, the role of which in genetic and hormonal reg

85 factors subsequently upregulate INDEHISCENT (IND) and SPATULA and are indispensable for the binding o

86 s (mucilaginous seed (M(+) ) vs indehiscent (IND) fruit) in the dimorphic annual Aethionema arabicum

87 tients with the asymptomatic (indeterminate, IND) or the cardiac (CCC) clinical forms is crucial for

88 eroidal anti-inflammatory drug indomethacin (IND) on MDSCs, depending on whether they were derived fr

89 To test this hypothesis, indomethacin (IND)-treated peripheral blood mononuclear cell (PBL) cul

90 Administration of indomethacin (IND) leads to the formation of lipid rafts and activatio

91 by conjugating the IDO inhibitor, indoximod (IND), to a phospholipid that allows prodrug self-assembl

92 death, which is synergistic with Indoximod (IND) inhibiting the IDO pathway to activate immune respo

93 data supported the nomination of CC-671 into IND-enabling studies as a single agent TNBC therapy.

94 Mechanistically, IND reduced arginase activity as well as NO and reactive

95 th the phenotypic plasticity to produce more IND fruit diaspores in colder temperatures, this constit

96 Immediate neurodeficit (IND) occurred in 79 (4.2%) and delayed in 104 (5.5%).

97 In a model of autoimmune neuroinflammation, IND-treated MDSCs differentiated in TFME attenuated infl

98 e made prediabetic via diet-induced obesity, IND was no longer effective in increasing long-term obje

99 ils the dual and context-dependent action of IND, a drug that serves both as an anti-inflammatory and

100 correlated with the suppressive activity of IND-treated MDSCs.

101 d is required to prevent ectopic activity of IND.

102 ULA and are indispensable for the binding of IND to some of its targets to allow stigma differentiati

103 Here we perform phylogenetic comparison of IND genes in Arabidopsis and Brassica to identify conser

104 fection, leading to successful completion of IND-enabling safety studies.

105 mechanism that results in the expression of IND in a narrow stripe of cells.

106 these sites simultaneously, the presence of IND at the catalytic site blocked binding at the effecto

107 ted the association of either two 4MP or one IND molecule(s) to CYP2E1, respectively.

108 ximately 110) x S. spontaneum (IND 81-146 or IND, 2n approximately 7x approximately 56) interspecific

109 The nanovesicles plus free OX or OX/IND-MSNP induce effective innate and adaptive anti-PDAC

110 , clinical trials (n = 3) and single patient IND (n = 1).

111 Compared with placebo, IND-GLY increased mean Q (LS means treatment difference:

112 c stem and progenitor cells (HSPCs); and pre-IND studies showing favorable Rebecsinib toxicokinetic a

113 ucts were strongly encouraged to prepare pre-IND packets and submit pre-IND meeting requests to the F

114 ed to prepare pre-IND packets and submit pre-IND meeting requests to the Food and Drug Administration

115 cuity, Indian Vision Function Questionnaire (IND-VFQ), and Medical Outcomes Study 36-item Short Form

116 V), Indian Visual Functioning Questionnaire (IND-VFQ), Spaeth/Richman Contrast Sensitivity (SPARCS) t

117 e (the Indian Visual Function Questionnaire [IND-VFQ]) were compared using Pearson correlation tests.

118 espectively, in patients with COPD receiving IND/GLY versus placebo.

119 arkably, addition of IFN-gamma also restored IND-suppressed IgG2 but not IgG1.

120 nscriptome and hormone analyses of M+ seeds, IND fruits, and M- seeds provided comprehensive datasets

121 rum officinarum Green German x S. spontaneum IND 81-146, and S. spontaneum PIN 84-1 x S. officinarum

122 tely 11x approximately 110) x S. spontaneum (IND 81-146 or IND, 2n approximately 7x approximately 56)

123 TPM is undergoing NIH-supported IND-enabling studies for clinical evaluation.

124 ndritic spines observed in the human APP(SWE,IND)-expressing transgenic mouse model in vivo.

125 mpal cells (HT22) expressing mutant APP (SWI/IND) mutations.

126 UA, 29% in P-PER, 29% in K-RWA, and 11% in T-IND (all P < 0.001).

127 minutes in K-RWA, and 31 +/- 19 minutes in T-IND.

128 za, Rwanda (K-RWA); and Tamil Nadu, India (T-IND).

129 itiated between 2000 and 2009, we found that IND-to-approval rates reduced to 23%, with median develo

130 The IND map consisted of 46 marker loci assembled into 10 LG

131 p hormone contents, identified a role of the IND pericarp in imposing coat dormancy by generating hyp

132 persal ability and degree of dormancy on the IND fruit morph to support telechory, while the M(+) see

133 ood and Drug Administration-approved via the IND (investigational new drug) compassionate-care route.

134 ICS with Indacaterol and Tiotropium (IND/TIO) vs ICS with Indacaterol (IND) over 4 weeks with

135 fic changes in patients with CCC compared to IND chronic Chagas disease, highlighted by distinct gene

136 were between 0.004 and 0.022) in response to IND/GLY versus placebo.

137 f oral sodium nitrite and nitrate treatment (IND#115926) displayed increased activation of SIRT3 and

138 We performed a phase I/II trial (IND#70627) of sterile pyrogen-free I-methylene blue to i

139 ss trial in two patients with infantile TSD (IND 18225) with safety as the primary endpoint and no se

140 We use IND to assess the relative reduction in IND from choosin

141 T cells were able to rapidly eradicate Vacc-IND-G from peripheral organs, to mediate delayed-type hy

142 nt vaccinia virus expressing the VSV-G (Vacc-IND-G).

143 ent groups for each QoL assessment (NEI-VFQ, IND-VFQ, PCS SF-36v2, and MCS SF-36v2; P > 0.05 for all)

144 lfactory glomeruli, suppression of Kv1.3 via IND had no effect on body weight nor the size and number

145 f WD534tc/C alone or combined with virulent (IND/A) or attenuated (NCDV/A) bovine group A rotaviruses

146 te motif (TRIM) family of proteins, is a VSV(IND) inhibitor.

147 tion of the viral machinery required for VSV(IND) RNA synthesis.IMPORTANCE Interferons are important

148 esicular stomatitis virus (VSV) Indiana (VSV(IND)), is a model virus that is exceptionally sensitive

149 TRIM69 potently inhibited VSV(IND) replication through a previously undescribed transc

150 ular stomatitis virus, Indiana serotype (VSV(IND)), a prototype negative-strand RNA virus.

151 y, TRIM69 physically associates with the VSV(IND) phosphoprotein (P), requiring a specific peptide ta

152 tly impedes all downstream events in the VSV(IND) replication cycle.

153 d (S)-2 showed favorable profiles in 16-week IND-enabling toxicology studies in dogs and rats.

154 Of the 193 markers analyzed, 61 were IND-specific, 106 were GG-specific, and 26 were heterozy

155 ted in TFME attenuated inflammation, whereas IND-treated MDSCs differentiated in TME aggravated clini

156 ) and 1 of 2 eyes with IPFS and 0 of 10 with IND in the PACG group (P < .05).

157 en in 6 of 7 eyes with IPFS and 1 of 13 with IND in the POAG group (P < .05) and 1 of 2 eyes with IPF

158 ce bearing the LP07 lung adenocarcinoma with IND inhibited the suppressive activity of splenic MDSCs,

159 determine the effect of lung deflation with IND/GLY on PMBF and regional pulmonary ventilation using

160 ilation was also significantly improved with IND/GLY, as evidenced by a 12.4% increase versus placebo

161 Conclusions: Pharmacologic intervention with IND/GLY improves pulmonary microvascular blood flow and

162 ononuclear cells obtained from patients with IND and CCC to unravel the immune landscape in these pol

163 ct was observed when MDSCs were treated with IND and conditioned media from LP07 tumor cells in vitro